| Dr Omar Hammam El Abd, MD | |
|
378 Washington St, Wellesley, MA 02481-6207 | |
| (781) 489-5541 | |
| (781) 489-5340 |
| Full Name | Dr Omar Hammam El Abd |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 29 Years |
| Location | 378 Washington St, Wellesley, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831189364 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | MD217195 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Newton-wellesley Hospital | Newton, MA | Hospital |
| Massachusetts General Hospital | Boston, MA | Hospital |
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Newton Wellesley Interventional Spine Llc | 8426289083 | 2 |
News Archive
Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).
The six industry groups that pledged to reduce health care spending growth by $2 trillion over 10 years on Friday issued a statement reaffirming their commitment to work toward the goal, Roll Call reports (Murray, Roll Call, 5/15).
Two new potential therapeutic targets for the treatment of pulmonary arterial hypertension, a deadly disease marked by high blood pressure in the lungs, have been identified by researchers at the University of Illinois at Chicago.
Alzheimer's Research UK, the UK's leading dementia research charity, is calling for an urgent plan for managing how new medicines are brought to patients, in a report that highlights several obstacles it fears could delay delivery of the next wave of dementia treatments.
A research team at the Ludwig Institute and Uppsala University has discovered an entirely new signal path for a growth factor that is of crucial importance for the survival and growth of cancer cells.
› Verified 7 days ago
| Entity Name | Newton Wellesley Interventional Spine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881027746 PECOS PAC ID: 8426289083 Enrollment ID: O20140324001413 |
News Archive
Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).
The six industry groups that pledged to reduce health care spending growth by $2 trillion over 10 years on Friday issued a statement reaffirming their commitment to work toward the goal, Roll Call reports (Murray, Roll Call, 5/15).
Two new potential therapeutic targets for the treatment of pulmonary arterial hypertension, a deadly disease marked by high blood pressure in the lungs, have been identified by researchers at the University of Illinois at Chicago.
Alzheimer's Research UK, the UK's leading dementia research charity, is calling for an urgent plan for managing how new medicines are brought to patients, in a report that highlights several obstacles it fears could delay delivery of the next wave of dementia treatments.
A research team at the Ludwig Institute and Uppsala University has discovered an entirely new signal path for a growth factor that is of crucial importance for the survival and growth of cancer cells.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Omar Hammam El Abd, MD 378 Washington St, Wellesley, MA 02481-6207 Ph: (781) 489-5541 | Dr Omar Hammam El Abd, MD 378 Washington St, Wellesley, MA 02481-6207 Ph: (781) 489-5541 |
News Archive
Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).
The six industry groups that pledged to reduce health care spending growth by $2 trillion over 10 years on Friday issued a statement reaffirming their commitment to work toward the goal, Roll Call reports (Murray, Roll Call, 5/15).
Two new potential therapeutic targets for the treatment of pulmonary arterial hypertension, a deadly disease marked by high blood pressure in the lungs, have been identified by researchers at the University of Illinois at Chicago.
Alzheimer's Research UK, the UK's leading dementia research charity, is calling for an urgent plan for managing how new medicines are brought to patients, in a report that highlights several obstacles it fears could delay delivery of the next wave of dementia treatments.
A research team at the Ludwig Institute and Uppsala University has discovered an entirely new signal path for a growth factor that is of crucial importance for the survival and growth of cancer cells.
› Verified 7 days ago
James R Gorman, M.D. Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 888 Worcester St Ste 95, Wellesley, MA 02482 Phone: 508-789-7471 |